First-generation epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKI) including geiftinib and erlotinib have been the standard first-line treatment for metastatic non-small-cell lung cancer (NSCLC) harboring activating EGFR mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.